› 4mwr

X-ray diffraction
1.8Å resolution

Anhui N9-zanamivir

Released:
DOI: 10.2210/pdb4mwr/pdb
PDB entry 4mwr coloured by chain, front view.
PDB entry 4mwr coloured by chain, side view.
PDB entry 4mwr coloured by chain, top view.
Source organism: Influenza A virus
Primary publication:
Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses.
Wu Y, Bi Y, Vavricka CJ, Sun X, Zhang Y, Gao F, Zhao M, Xiao H, Qin C, He J, Liu W, Yan J, Qi J, Gao GF
OpenAccess logo Cell Res 23 1347-55 (2013)
PMID: 24165891

Function and Biology Details

Reaction catalysed: 
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates.
Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
homo tetramer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-100101 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecules (2 distinct):
Neuraminidase Chain: A
Molecule details ›
Chain: A
Length: 388 amino acids
Theoretical weight: 43.55 KDa
Source organism: Influenza A virus
Expression system: Spodoptera frugiperda
UniProt:
  • Canonical: A0A024E3Q2 (Residues: 78-465; Coverage: 83%)
Gene name: NA
Sequence domains: Neuraminidase
Structure domains: Neuraminidase

Ligands and Environments

Carbohydrate polymer : NEW Components: NAG, BMA, MAN
Carbohydrate polymer
3 bound ligands:
Ligand NAG 2 x NAG
Ligand CA 1 x CA
Ligand ZMR 1 x ZMR
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: SSRF BEAMLINE BL17U
Spacegroup: I432
Unit cell:
a: 181.533Å b: 181.533Å c: 181.533Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.148 0.147 0.173
Expression system: Spodoptera frugiperda

Quick links

Citations

11 review citations

Pandemic potential of avian influenza A (H7N9) viruses.
Watanabe et al. (2014)
10 more

4 mentions without citation

The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs.
Li et al. (2023)
3 more